Get started
Author

Valeriy Viktorovich Kulagin

Observed names: V. Kulagin, V. V Kulagin, V. V. Kulagin, V.V. Kulagin, V.V.Kulagin V.V.Kulagin, Valeriy Kulagin, Valery V. Kulagin, Кулагин Валерий Викторович
ORCID: 0009-0006-3613-0060
Observed ORCID: 0009-0006-3613-0060
OpenAlex ID: A5108742362
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
2018 · Pedro Cahn, Juan Sierra Madero, et al. · The Lancet · 406
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 155
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
2019 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 100
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 38
HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006–2022
2023 · Alina Kirichenko, Dmitry Kireev, et al. · Viruses · 20
PDF
Hiv Drug Resistance Early Warning Indicators and Their Assessment in Some Regions of Russia
2019 · N. N. Lebedeva, S. Ya. Zverev, et al. · HIV Infection and Immunosuppressive Disorders · 8
PDF
Genetic profile and characteristics of HIV-1 drug resistance mutation in the Krasnodar region over the 2014 to 2019
2022 · А. А. Antonova, А. S. Tumanov, et al. · HIV Infection and Immunosuppressive Disorders · 7
PDF
Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
2019 · C. Orkin, N. Porteiro, et al. · Journal of Infection and Public Health · 1
PDF
Assessment of the effectiveness of determining the duration of HIV infection by analysis of viral genetic variability
2017 · D.E.Kireev D.E.Kireev, A.V.Murzakova A.V.Murzakova, et al. · Infekcionnye bolezni · 1
Current CMV infection at pregnant HIV-infected of women
2016 · L.I. Zhukova, Yu.G. Shakhverdyan, et al. · Infekcionnye bolezni · 1
1617Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
2014 · Hedy Teppler, Andrey Shuldyakov, et al. · Open Forum Infectious Diseases · 1
PDF
HIV-1 genetic variants and transmitted drug resistance among recent infected individuals in Krasnodar Region, 2014-2022
2026 · Anastasia V. Shlykova, Arina V. Syrkina, et al. · Journal of microbiology epidemiology immunobiology
PDF
The Case of Death From Liver Cirrhosis in the Female Patient With Hiv Infection and Infiltrative Pulmonary Tuberculosis
2013 · I. Yu. Babaeva, M. G. Avdeeva, et al. · Epidemiology and Infectious Diseases
Случай смерти от цирроза печени больной с ВИЧ-инфекцией и инфильтративным туберкулезом легких
2013 · Бабаева Ирина Юрьевна, Авдеева Марина Геннадьевна, et al. · Epidemiology and Infectious Diseases
Works count: 14
Citation count: 736
H-index: 7
I10-index: 5
Year
Topic
Type